Akoya Biosciences (AKYA) Stock Forecast, Price Target & Predictions
AKYA Stock Forecast
Akoya Biosciences stock forecast is as follows: an average price target of $7.90 (represents a 174.31% upside from AKYA’s last price of $2.88) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKYA Price Target
The average price target for Akoya Biosciences (AKYA) is $7.90 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $3.00. This represents a potential 174.31% upside from AKYA's last price of $2.88.
AKYA Analyst Ratings
According to 5 Wall Street analysts, Akoya Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for AKYA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Akoya Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Tejas Savant | Morgan Stanley | $3.00 | $2.01 | 49.25% | 4.17% |
| Jun 21, 2024 | Bill Bonello | Craig-Hallum | $7.50 | $2.23 | 236.32% | 160.42% |
| Jun 03, 2024 | Tejas Savant | Morgan Stanley | $4.00 | $2.15 | 86.05% | 38.89% |
| May 14, 2024 | Mark Massaro | BTIG | $6.00 | $4.12 | 45.63% | 108.33% |
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $6.00 | $4.12 | 45.63% | 108.33% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $17.00 | $13.34 | 27.44% | 490.28% |
The latest Akoya Biosciences stock forecast, released on Aug 06, 2024 by Tejas Savant from Morgan Stanley, set a price target of $3.00, which represents a 49.25% increase from the stock price at the time of the forecast ($2.01), and a 4.17% increase from AKYA last price ($2.88).
Akoya Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $5.25 | $5.30 |
| Last Closing Price | $2.88 | $2.88 | $2.88 |
| Upside/Downside | -100.00% | 82.29% | 84.03% |
In the current month, the average price target of Akoya Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akoya Biosciences's last price of $2.88. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Aug 06, 2024 | BTIG | Buy | Neutral | Downgrade |
| Jun 21, 2024 | Craig-Hallum | - | Buy | Initialise |
| Jun 03, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 14, 2024 | BTIG | Buy | Buy | Hold |
| May 14, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jan 04, 2023 | BTIG | Buy | Buy | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Akoya Biosciences's last stock rating was published by Morgan Stanley on Aug 06, 2024. The company Downgrade its AKYA rating from "Overweight" to "Equal-Weight".
Akoya Biosciences Financial Forecast
Akoya Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.49M | $25.21M | $23.52M | $21.41M | $21.22M | $18.85M | $17.89M | $16.89M | $16.16M | $13.48M | $13.07M | $12.21M |
| Avg Forecast | $35.90M | $32.34M | $30.57M | $27.49M | $34.18M | $29.41M | $27.35M | $24.32M | $30.77M | $25.43M | $23.43M | $24.35M | $26.14M | $24.51M | $22.39M | $20.32M | $20.47M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| High Forecast | $38.11M | $34.34M | $32.46M | $29.19M | $36.29M | $31.23M | $29.04M | $25.82M | $32.66M | $26.02M | $24.88M | $25.85M | $26.25M | $26.03M | $23.77M | $21.57M | $21.73M | $18.68M | $17.64M | $15.56M | $16.18M | $13.62M | $13.12M | $12.54M |
| Low Forecast | $33.74M | $30.39M | $28.74M | $25.84M | $32.13M | $27.64M | $25.70M | $22.86M | $28.91M | $25.03M | $22.02M | $22.88M | $26.02M | $23.04M | $21.04M | $19.09M | $19.23M | $16.53M | $16.27M | $14.36M | $14.93M | $12.57M | $12.11M | $11.57M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.03% | 1.05% | 1.05% | 1.04% | 1.07% | 1.06% | 1.13% | 1.04% | 1.03% | 1.04% | 1.02% |
Akoya Biosciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $24.35M, with a low forecast of $22.88M, and a high forecast of $25.85M. AKYA's average Quarter revenue forecast represents a -8.09% decrease compared to the company's last Quarter revenue of $26.49M (Dec 23).
Akoya Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-11.20M | $-12.79M | $-16.23M | $-14.52M | $-14.80M | $-14.57M | $-16.08M | $-13.81M | $-21.87M | $-9.62M | $-3.68M | $-6.30M |
| Avg Forecast | $-16.63M | $-14.98M | $-14.16M | $-12.73M | $-15.83M | $-13.62M | $-12.67M | $-11.26M | $-14.25M | $-11.78M | $-10.85M | $-11.28M | $-12.11M | $-11.35M | $-10.37M | $-9.41M | $-9.48M | $-8.55M | $-7.84M | $-12.21M | $-7.19M | $-6.05M | $-5.83M | $-106.66M |
| High Forecast | $-15.63M | $-14.08M | $-13.31M | $-11.97M | $-14.88M | $-12.80M | $-11.91M | $-10.59M | $-13.39M | $-11.59M | $-10.20M | $-10.60M | $-12.05M | $-10.67M | $-9.75M | $-8.84M | $-8.91M | $-6.84M | $-7.54M | $-9.77M | $-6.91M | $-5.82M | $-5.61M | $-85.33M |
| Low Forecast | $-17.65M | $-15.90M | $-15.04M | $-13.52M | $-16.81M | $-14.46M | $-13.45M | $-11.96M | $-15.13M | $-12.05M | $-11.52M | $-11.97M | $-12.16M | $-12.06M | $-11.01M | $-9.99M | $-10.06M | $-10.26M | $-8.17M | $-14.66M | $-7.49M | $-6.31M | $-6.08M | $-127.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.13% | 1.57% | 1.54% | 1.56% | 1.70% | 2.05% | 1.13% | 3.04% | 1.59% | 0.63% | 0.06% |
undefined analysts predict AKYA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akoya Biosciences's previous annual EBITDA (undefined) of $NaN.
Akoya Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.80M | $-12.92M | $-20.80M | $-18.80M | $-18.88M | $-17.87M | $-17.50M | $-16.40M | $-17.67M | $-11.62M | $-5.56M | $-8.08M |
| Avg Forecast | $-988.40K | $-2.97M | $-5.44M | $-10.38M | $-3.55M | $-6.04M | $-7.48M | $-9.69M | $-4.75M | $-10.05M | $-13.17M | $-14.27M | $-13.29M | $-17.65M | $-21.76M | $-23.66M | $-21.42M | $-10.32M | $-18.38M | $-14.30M | $-15.28M | $-12.85M | $-11.43M | $-136.92M |
| High Forecast | $-911.09K | $-2.73M | $-5.01M | $-9.57M | $-3.27M | $-5.57M | $-6.90M | $-8.93M | $-4.38M | $-8.46M | $-12.14M | $-13.15M | $-12.30M | $-16.27M | $-20.06M | $-21.81M | $-19.75M | $-8.26M | $-17.47M | $-11.44M | $-14.53M | $-12.22M | $-10.86M | $-109.53M |
| Low Forecast | $-1.07M | $-3.20M | $-5.87M | $-11.21M | $-3.84M | $-6.52M | $-8.08M | $-10.47M | $-5.14M | $-10.58M | $-14.22M | $-15.42M | $-14.27M | $-19.06M | $-23.51M | $-25.56M | $-23.14M | $-12.39M | $-19.40M | $-17.16M | $-16.12M | $-13.56M | $-12.06M | $-164.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.73% | 0.96% | 0.79% | 0.88% | 1.73% | 0.95% | 1.15% | 1.16% | 0.90% | 0.49% | 0.06% |
Akoya Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKYA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akoya Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $18.90M | $19.02M | $22.71M | $21.76M | $20.95M | $19.92M | $20.59M | $18.19M | $19.05M | $13.72M | $10.07M | $8.18M |
| Avg Forecast | $28.96M | $26.09M | $24.67M | $22.18M | $27.58M | $23.73M | $22.07M | $19.62M | $24.82M | $20.52M | $18.90M | $19.64M | $21.09M | $19.78M | $18.07M | $16.39M | $16.51M | $12.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| High Forecast | $30.75M | $27.71M | $26.19M | $23.55M | $29.29M | $25.20M | $23.43M | $20.84M | $26.36M | $21.00M | $20.07M | $20.86M | $21.18M | $21.00M | $19.18M | $17.40M | $17.53M | $14.63M | $14.23M | $12.56M | $13.05M | $10.99M | $10.59M | $10.12M |
| Low Forecast | $27.22M | $24.52M | $23.19M | $20.85M | $25.92M | $22.31M | $20.74M | $18.44M | $23.33M | $20.20M | $17.77M | $18.46M | $20.99M | $18.59M | $16.98M | $15.41M | $15.52M | $9.76M | $13.13M | $11.59M | $12.05M | $10.14M | $9.77M | $9.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.96% | 1.26% | 1.33% | 1.27% | 1.63% | 1.51% | 1.51% | 1.52% | 1.30% | 0.99% | 0.84% |
Akoya Biosciences's average Quarter SG&A projection for Mar 24 is $19.64M, based on 4 Wall Street analysts, with a range of $18.46M to $20.86M. The forecast indicates a 3.95% rise compared to AKYA last annual SG&A of $18.90M (Dec 23).
Akoya Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.26 | $-0.51 | $-0.49 | $-0.50 | $-0.47 | $-0.47 | $-0.44 | $-0.47 | $-0.31 | $-0.20 | $-0.23 |
| Avg Forecast | $-0.02 | $-0.06 | $-0.11 | $-0.21 | $-0.07 | $-0.12 | $-0.15 | $-0.20 | $-0.10 | $-0.20 | $-0.27 | $-0.29 | $-0.27 | $-0.36 | $-0.44 | $-0.48 | $-0.43 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| High Forecast | $-0.02 | $-0.06 | $-0.10 | $-0.19 | $-0.07 | $-0.11 | $-0.14 | $-0.18 | $-0.09 | $-0.17 | $-0.25 | $-0.27 | $-0.25 | $-0.33 | $-0.41 | $-0.44 | $-0.40 | $-0.41 | $-0.35 | $-0.37 | $-0.29 | $-0.25 | $-0.22 | $-0.16 |
| Low Forecast | $-0.02 | $-0.06 | $-0.12 | $-0.23 | $-0.08 | $-0.13 | $-0.16 | $-0.21 | $-0.10 | $-0.21 | $-0.29 | $-0.31 | $-0.29 | $-0.39 | $-0.48 | $-0.52 | $-0.47 | $-0.47 | $-0.39 | $-0.41 | $-0.33 | $-0.27 | $-0.24 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.73% | 1.16% | 1.02% | 1.15% | 1.07% | 1.26% | 1.14% | 1.52% | 1.19% | 0.86% | 1.35% |
According to undefined Wall Street analysts, Akoya Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKYA previous annual EPS of $NaN (undefined).
Akoya Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.88 | $7.90 | 174.31% | Buy |
| COO | Cooper Companies | $109.83 | $298.00 | 171.33% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| ATRC | AtriCure | $28.07 | $49.57 | 76.59% | Buy |
| HAE | Haemonetics | $76.54 | $104.33 | 36.31% | Buy |
| LMAT | LeMaitre Vascular | $88.82 | $81.67 | -8.05% | Buy |
| ICUI | ICU Medical | $176.29 | $135.00 | -23.42% | Buy |
| ATR | AptarGroup | $153.03 | $100.00 | -34.65% | Buy |
AKYA Forecast FAQ
Is Akoya Biosciences a good buy?
Yes, according to 5 Wall Street analysts, Akoya Biosciences (AKYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of AKYA's total ratings.
What is AKYA's price target?
Akoya Biosciences (AKYA) average price target is $7.9 with a range of $3 to $17, implying a 174.31% from its last price of $2.88. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Akoya Biosciences stock go up soon?
According to Wall Street analysts' prediction for AKYA stock, the company can go up by 174.31% (from the last price of $2.88 to the average price target of $7.9), up by 490.28% based on the highest stock price target, and up by 4.17% based on the lowest stock price target.
Can Akoya Biosciences stock reach $4?
AKYA's average twelve months analyst stock price target of $7.9 supports the claim that Akoya Biosciences can reach $4 in the near future.
What are Akoya Biosciences's analysts' financial forecasts?
Akoya Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $115.27M (high $122.38M, low $108.33M), average EBITDA is $-53.388M (high $-50.176M, low $-56.685M), average net income is $-26.763M (high $-24.67M, low $-28.911M), average SG&A $93.01M (high $98.75M, low $87.41M), and average EPS is $-0.542 (high $-0.499, low $-0.585). AKYA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $126.3M (high $134.1M, low $118.7M), average EBITDA is $-58.499M (high $-54.979M, low $-62.11M), average net income is $-19.768M (high $-18.222M, low $-21.354M), average SG&A $101.91M (high $108.2M, low $95.78M), and average EPS is $-0.4 (high $-0.369, low $-0.432).
Did the AKYA's actual financial results beat the analysts' financial forecasts?
Based on Akoya Biosciences's last annual report (Dec 2023), the company's revenue was $96.63M, beating the average analysts forecast of $93.36M by 3.51%. Apple's EBITDA was $-64.057M, beating the average prediction of $-43.241M by 48.14%. The company's net income was $-63.323M, missing the average estimation of $-76.352M by -17.06%. Apple's SG&A was $82.38M, beating the average forecast of $75.33M by 9.36%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-1.545 by -99.91%. In terms of the last quarterly report (Dec 2023), Akoya Biosciences's revenue was $26.49M, beating the average analysts' forecast of $26.14M by 1.34%. The company's EBITDA was $-11.199M, missing the average prediction of $-12.106M by -7.49%. Akoya Biosciences's net income was $-10.802M, missing the average estimation of $-13.285M by -18.69%. The company's SG&A was $18.9M, missing the average forecast of $21.09M by -10.39%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-0.269 by -99.93%